Swiss biotech companies reached new heights in fundraising last year, led by genetic editing specialist– registered in Zug – and its 940 million francs, in front of the Rhine laboratory and its 866 million. The introduction to the Lausanne Nasdaq generated 470 million, underlines Tuesday the annual report of the segment compiled by the firm EY.
Among the unlisted companies, the Basel-based Vactivbio with 135 million, the Geneva-based Sophia Genetics with 100 million or even the young Rhine company Noema Pharma with 54 million have stood out. The segment as a whole thus garnered 3.44 billion.
Measured in the light of patents, Switzerland’s competitiveness in terms of innovation remained at the forefront for a tenth consecutive year. Notwithstanding the diversion imposed by the fight against the Covid-19 pandemic, laboratories continued to increase their investments in research and development, by 10% to 2.2 billion.
The health crisis will have made it possible to highlight both the importance of the Swiss academic place in fundamental research and that of private developers of diagnostic solutions, such as Roche, but also Quotient, Mosaiq and Biolytix, shouts the report.
Vaccines and experimental treatments
On the vaccine side, subcontractors Lonza and Bachem, and Janssen Cilag took center stage. The partnerships between Molecular Partners and Novartis or even Humabs Biomed and Vir Boitechnologies have been illustrated in the field of experimental treatments.
The segment’s total revenues suffered from a basis of comparison marked by exceptional collaboration products, falling to 4.5 million against 4.8 billion a year earlier. Revenues from the products marketed nevertheless continued to rise.
On the front of mergers and collaborations, the Japanese Sumitomo Dainippon Pharma has notably injected 3.0 billion dollars into its alliance with the Rhine incubator Roivant Sciences to found Sumitovant Biopharma.